Tryton Medical Obtains $5,000,000 New Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b2b85dfd-8055-4cb8-b323-5cee2b3deabd&Preview=1 - Date
5/3/2011 - Company Name
Tryton Medical - Mailing Address
1000 Park Forty Plaza Durham, MA 27713 - Company Description
Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery. - Website
http://www.trytonmedical.com - Transaction Type
Debt - Transaction Amount
$5,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
With the help of this new credit facility, the company is enrolling in a pivotal US clinical trial. - M&A Terms
- Venture Investor
Square 1 Bank
